Providence Hematologic Malignancies Program

Hematologic malignancies include Hodgkin and non-Hodgkin lymphomas, leukemias, myeloma and the myelodysplastic syndromes. These malignancies are diverse, and their treatment is complex.

Our team of physicians are experts in the care of these diseases. Providence Hematologic Malignancies Program at Providence Cancer Center is primarily focused on developing new immuno-oncology therapies for these diseases. Immuno-oncology utilizes the body’s own immune system to fight cancer. Treatment for some hematologic malignancies may also be available through the Providence Autologous Stem Cell Transplant Program.

The immune system has immense potential to trigger the specific destruction of tumors while sparing normal tissue. Our clinicians are working with research scientists at the Earle A. Chiles Research Institute, as well as external collaborations to bring and develop new immuno-oncology approaches to treating leukemia, MDS, myleloma and Hodgkin and non-Hodgkin lymphoma.

We are a American Society of Clinical Oncology Quality Oncology Practice Initiative (QOPI) certified team of providers with the experience and ability to deliver the best care and highest quality survival in Oregon and the Pacific Northwest, for patients with hematologic (blood) malignancies.

Our program utilizes a multidisciplinary care approach to ensure the highest quality, patient-focused experience in clinical care. We offer second opinions on complex hematologic malignancies. We provide a unique set of cutting-edge clinical and translational research trials with the most promising agents for Oregonians with these blood related malignancies. Many of our trials are first-in-man studies of new immuno-oncology therapies. 

Current projects

  • Novel phase I and II, clinical trials of new immuno-oncology therapy treatments for lymphoma.
  • Development of novel Immune therapy approaches to treat MDS and AML leukemias.
  • Novel immunotherapy after autologous bone marrow transplant for patients with myeloma and non-Hodgkin lymphoma.